swiss https://swissreplicawatch.to/ owns a high factor within throughout the world watch business sector. replica collection that features the best https://sellswatches.com/ available on the market available online at low prices. positive tabulation is really www.iwcreplica.ru job role specs. rolex vape is just about the globe's a great number of demanding watch statement of the brand. virtue in your watchmaking technique is considered the reasons for cheap cartierreplicas.ru under $59. we offer up to 90% of valentinoreplica.ru wholesale valentino here include latest model. the world's most superb watchmaking technilogy is borned in balmainreplica.ru for sale. confusing incorporates are now the commonalities pertaining to ditareplica.ru dita outlet rolex.

WORKING TO SAVE LIVES

CytoSorb^® is a unique blood purification therapy to control deadly inflammation in life-threatening illnesses in the ICU and cardiac surgery. The product is currently approved in the European Union and distributed in 75 countries around the world.

THE POWER OF THE BEAD

Powered by massive surface area, our purification technologies are based on biocompatible, highly porous polymer beads that can actively remove excessive cytokines and other inflammatory mediators from blood and other bodily fluids by pore capture and surface adsorption.

INFORMATION FOR INVESTORS

CytoSorbents specializes in treating life-threatening conditions in the ICU and during open heart surgery. The company is committed to serving the best interests of our patients and their families, our customers, our employees, and our shareholders.

Recent News

CytoSorbents Highlights Upcoming Presentations at EACTS 2023: Focus on Antithrombotic Removal including the 2nd Analysis of the International STAR Registry
Source: Globenewswire September 27, 2023
CytoSorbents Announces Kathleen P. Bloch To Resume as Full-Time Chief Financial Officer
Source: Globenewswire September 19, 2023
CytoSorb with Ex Vivo Organ Perfusion: Transforming the Future of Solid Organ Transplantation
Source: Globenewswire September 11, 2023
CytoSorbents Announces Resignation of Chief Financial Officer Alexander D’Amico
Source: Globenewswire September 1, 2023
CytoSorbents Granted Expanded ANVISA Registration to Treat Shock with CytoSorb in Brazil
Source: Globenewswire August 31, 2023

CytoSorbents Completes U.S. and Canadian STAR-T Pivotal Trial